Compugen And Biosite Announce Diagnostic Collaboration
Tel Aviv, Israel and San Diego, CA – Compugen Ltd. and Biosite® Incorporated announced today a collaboration for the development and commercialization of diagnostic products. Under the agreement, Biosite is licensed to develop and commercialize immunoassay based diagnostic products using novel biomarkers discovered by Compugen. Using its genomic platform and other proprietary computational tools, Compugen is expected to provide Biosite with comprehensive data on several gene targets to be nominated by Biosite.
Under the terms of the agreement, Compugen grants to Biosite an exclusive license to use the selected Compugen targets for immunoassay based diagnostic applications. In return, Compugen is to receive milestone payments and royalties from the sales of each diagnostic product emerging from the collaboration. Compugen retains the exclusive right to pursue further development in the therapeutic field and Biosite will be entitled to receive from Compugen milestone payments and royalties arising from any successful therapeutic application.
The collaboration combines Biosite's expertise in rapid, high- affinity antibody development and successful commercialization of proprietary testing platforms consisting of both individual diagnostic markers and panels of markers with Compugen's unique discovery capabilities. Compugen's discovery process relies on the comprehensive predictive analysis of the human proteome provided by the Company's genomic platform. The result of this analysis is utilized with a variety of discovery engines, each designed to identify novel proteins with specific characteristics from the vast numbers predicted by the discovery process.
"We are looking forward to working in collaboration with Compugen," said Gunars Valkirs, Ph.D., Biosite's Senior Vice President, Discovery. "We hope that this partnership will enable access to novel markers in areas of strategic focus to Biosite that will lead to new product opportunities for us."
Mor Amitai, President and Chief Executive Officer of Compugen, said, "We are excited about the opportunity to collaborate with Biosite, a leading provider of rapid diagnostic products and antibody development technologies. This agreement marks Compugen's third diagnostic collaboration in less than a year, which we believe positions us as a leader in discovery of biomarker candidates. Our activities in diagnostic discovery complement our internal drug discovery efforts."
SOURCE: Compugen Ltd.